The relationship between cannabis and male infertility, sexual health, and neoplasm: a systematic review

Rajanahally, Saneal; Raheem, Omer; Rogers, Marc J.; Brisbane, Wayne; Ostrowski, Kevin; Lendvay, T.S.; Walsh, Thomas J.

doi:10.1111/andr.12585

Cited by 58 publications

(38 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies failed to demonstrate a decrease in sperm count in marijuana smokers [87]. A recent systematic review of seven clinical studies and 23 animal/in vitro studies concluded that cannabis consumption exerts a negative impact on semen parameters, but it considered also the alteration of sperm motility and morphology that is not an argument of our review [80].…”

Section: Effects On Spermatogenesismentioning

confidence: 79%

“…Despite animal studies showed a decreased testosterone production after exposition to cannabis, a clear relationship between marijuana use and hypogonadism has not been found in men. However, marijuana users have worse sperm parameters, including sperm total count and concentration, compared to controls in most studies [80].…”

Section: Discussionmentioning

confidence: 91%

“…A study on over 1,200 young healthy men reported, similarly to tobacco smokers, an increase in testosterone levels in marijuana smokers [79]. A recent systematic review on 15 clinical studies and 21 animal/in vitro studies concluded for a not significant relationship between long-term cannabis consumption and alteration of the hypothalamic-pituitary-testicular axis hormones [80].…”

Section: Effects On Testosterone Productionmentioning

confidence: 99%

See 2 more Smart Citations

Substance Abuse and Male Hypogonadism

Duca

Aversa

Condorelli

et al. 2019

JCM

View full text Add to dashboard Cite

Progressive deterioration of male reproductive function is occurring in Western countries. Environmental factors and unhealthy lifestyles have been implicated in the decline of testosterone levels and sperm production observed in the last fifty years. Among unhealthy lifestyles, substance and drug abuse is a recognized cause of possible alterations of steroidogenesis and spermatogenesis. Alcohol, opioids and anabolic-androgenic steroids are capable to reduce testosterone production in male interfering with testicular and/or hypothalamic-pituitary function. Other substances such as nicotine, cannabis, and amphetamines alter spermatogenesis inducing oxidative stress and subsequent apoptosis in testicular tissue. Substance and drug abuse is a potentially reversible cause of hypogonadism, defined as the failure of the testis to produce physiological concentrations of testosterone and/or a normal number of spermatozoa. The identification of the abuse is important because the withdrawal of substance intake can reverse the clinical syndrome. This review summarizes the most important clinical and experimental evidence on the effect of substance abuse on testosterone and sperm production.

show abstract

Section: Effects On Spermatogenesismentioning

confidence: 79%

Section: Discussionmentioning

confidence: 91%

Section: Effects On Testosterone Productionmentioning

confidence: 99%

See 1 more Smart Citation

Substance Abuse and Male Hypogonadism

Duca

Aversa

Condorelli

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…In this study, no differences in semen parameters were found comparing cannabis users with the rest of the sample. Recent systematic reviews support a negative effect of cannabis consumption on sperm parameters 109,110 and fertilizing capacity. 110 However, further studies are needed to validate these findings in relation to couple fertility.…”

Section: F I G U R Ementioning

confidence: 99%

The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: clinical, seminal and biochemical characteristics

et al. 2020

View full text Add to dashboard Cite

Background Infertility affects 7%‐12% of men, and its etiology is unknown in half of cases. To fill this gap, use of the male genital tract color‐Doppler ultrasound (MGT‐CDUS) has progressively expanded. However, MGT‐CDUS still suffers from lack of standardization. Hence, the European Academy of Andrology (EAA) has promoted a multicenter study (“EAA ultrasound study”) to assess MGT‐CDUS characteristics of healthy, fertile men to obtain normative parameters. Objectives To report (a) the development and methodology of the “EAA ultrasound study,” (b) the clinical characteristics of the cohort of healthy, fertile men, and (c) the correlations of both fertility history and seminal features with clinical parameters. Methods A cohort of 248 healthy, fertile men (35.3 ± 5.9 years) was studied. All subjects were asked to undergo, within the same day, clinical, biochemical, and seminal evaluation and MGT‐CDUS before and after ejaculation. Results The clinical, seminal, and biochemical characteristics of the cohort have been reported here. The seminal characteristics were consistent with those reported by the WHO (2010) for the 50th and 5th centiles for fertile men. Normozoospermia was observed in 79.6% of men, while normal sperm vitality was present in almost the entire sample. Time to pregnancy (TTP) was 3.0[1.0‐6.0] months. TTP was negatively correlated with sperm vitality (Adj.r =−.310, P = .011), but not with other seminal, clinical, or biochemical parameters. Sperm vitality and normal morphology were positively associated with fT3 and fT4 levels, respectively (Adj.r = .244, P < .05 and Adj.r = .232, P = .002). Sperm concentration and total count were negatively associated with FSH levels and positively, along with progressive motility, with mean testis volume (TV). Mean TV was 20.4 ± 4.0 mL, and the lower reference values for right and left testes were 15.0 and 14.0 mL. Mean TV was negatively associated with gonadotropin levels and pulse pressure. Varicocoele was found in 33% of men. Conclusions The cohort studied confirms the WHO data for all semen parameters and represents a reference with which to assess MGT‐CDUS normative parameters.

show abstract

“…Indeed, some studies have suggested a higher prevalence of erectile dysfunction (ED) among chronic cannabis users, whereas others have reported a prevalence that is equal to nonusers. 6 , 7 , 8 In a recent report, most male and female cannabis users endorsed increased sexual satisfaction, sensitivity, and orgasm intensity, with only a small fraction reporting orgasmic difficulty and some even reporting increased ability to orgasm. 9 Simultaneously, a large survey of Australian men found that daily cannabis use was associated with an inability to orgasm as desired, with either rapid ejaculation or delayed ejaculation.…”

Section: Introductionmentioning

confidence: 99%

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Bhambhvani

Kasman

Wilson-King³

2020

Sexual Medicine

View full text Add to dashboard Cite

Introduction Cannabis is the most commonly used drug in the United States; however, the effects of cannabis use on male sexual function are poorly understood. Aim To characterize the contemporary landscape of cannabis use and to assess the associations between male sexual function and the frequency of use, the primary method of consumption, or cannabis chemovar (tetrahydrocannabinol or cannabidiol) among current users. Methods We surveyed adults who visited a single cannabis dispensary for baseline demographic information, medical history, cannabis use habits, and sexual function as assessed by the International Index of Erectile Function (IIEF). An IIEF-5 < 21 was considered erectile dysfunction. Main Outcome Measures The main outcome measure of the study was male sexual function via the IIEF domain scores. Results A total of 325 men completed the survey with a mean age of 46.7 years. 71.1% of the men were Caucasian and 52.6% were married. 13 men (4%) were never users; 29 men (8.9%) used 1–2 times/week; 51 men (15.7%) used 3–5 times/week, and 232 men (71.4%) used 6+ times/week. The average IIEF-5 score was 22.3 with 19.4% of the men having erectile dysfunction. In univariate analysis, men using cannabis more frequently had a higher overall IIEF (65.36 vs 60.52, P = .001), erectile domain (27.32 vs 25.74, P = .03), orgasm domain (9.08 vs 8.12, P < .001), intercourse satisfaction domain (12.42 vs 11.31, P = .006), and overall satisfaction domain (8.11 vs 7.05, P = .002). In multivariable analysis, compared to men who used cannabis 0 times/week, those who used 6 times/week had an increased overall IIEF (69.08 vs 64.64, P -value adjusted = 0.02), intercourse satisfaction domain ( P -value adjusted = 0.04), and overall satisfaction domain ( P -value adjusted = 0.02). The primary method of consumption (eg, smoking, edibles, etc.) and cannabinoid composition (eg, cannabidiol vs tetrahydrocannabinol dominant) were not associated with sexual function. Conclusion We report an association between the increased frequency of cannabis use and increased male sexual function. However, while the increased frequency of use was statistically significant with regard to the IIEF scores, the clinical significance of this is likely low, and selection bias may limit the generalizability of these findings. The method of consumption and cannabis chemovar were not associated with sexual function. Bhambhvani HP, Kasman AM, Wilson-King G, et al. A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men. J Sex Med 2020;8:436–445.

show abstract

The relationship between cannabis and male infertility, sexual health, and neoplasm: a systematic review

Cited by 58 publications

References 54 publications

Substance Abuse and Male Hypogonadism

Substance Abuse and Male Hypogonadism

The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: clinical, seminal and biochemical characteristics

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Contact Info

Product

Resources

About